% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • ghosttraderg ghosttraderg Nov 17, 2011 3:48 PM Flag

    Corporate Presentation – November 2011

    Investment Highlights
     New AmiKet™ data in CIPN
    • Breakthrough efficacy in disease with high unmet medical
    • Partnership discussions ongoing
    • EOP2 Meeting with FDA scheduled for December 2011
     Ceplene® approved in EU, launched in UK, Germany, Italy and
    • Additional reimbursement filings in Spain, France and
    remainder of key approved countries in 2011
     Key investigator initiated trial strategy underway
     New Ceplene® US 4
    Phase III survival trial required for US filing

0.924-0.026(-2.75%)Nov 27 1:00 PMEST